デフォルト表紙
市場調査レポート
商品コード
1529772

半固形製剤受託製造の市場規模、シェア、動向分析レポート:タイプ別、製品別、最終用途別、企業規模別、地域別、セグメント予測、2024年~2030年

Semi-solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Topical, Transdermal, Oral), By Product (Creams, Gels), By End Use, By Company Size, By Region, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.54円
半固形製剤受託製造の市場規模、シェア、動向分析レポート:タイプ別、製品別、最終用途別、企業規模別、地域別、セグメント予測、2024年~2030年
出版日: 2024年07月16日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向

世界の半固形製剤受託製造の市場規模は2023年に175億7,000万米ドルとなり、2024年から2030年にかけてCAGR 11.12%で成長すると予測されています。皮膚疾患、関節炎、疼痛管理などの慢性疾患の有病率の増加と相まって、患者に優しい医薬品への需要が高まっていることが、市場の成長を後押ししています。さらに、費用対効果の高さから製造アウトソーシングの需要が高まっています。さらに、規制遵守と品質保証、製剤技術の革新を含む技術的進歩が、予測期間中の需要を押し上げる可能性が高いです。

皮膚疾患、関節炎などの慢性疾患の有病率の高さや、世界の高齢化に伴う疼痛管理ソリューションの必要性が、市場成長の主な要因となっています。世界保健機関(WHO)によると、常時3,000種類以上の皮膚疾患に罹患している人口は18億人と推定されており、効果的な治療に対する需要は非常に大きいです。米国では人口の高齢化が著しく進んでいます。人口問題研究所が2024年1月に発表したファクトシートによると、65歳以上のアメリカ人の数は、2022年の5,800万人から2050年には8,200万人に急増し、47%の大幅な増加が見込まれています。さらに、総人口に占める65歳以上の高齢者の割合は17%から23%に上昇し、米国史上最高齢の年齢分布になると予測されています。

さらに、世界疾病負担調査2021によると、皮膚疾患は世界の健康負担の第8位にランクされています。クリームや軟膏のような半固形製剤は、多くの皮膚疾患に好んで使用される投与方法であり、便利で雑味のない塗布が可能です。このような皮膚疾患や疼痛管理治療に対する需要の急増は、製薬会社がこれらの医薬品を効率的かつ大量に生産する専門知識を持つパートナーを求めているため、市場の成長を後押ししています。さらに、2019年から2021年までの期間をカバーするCDCの報告書によると、関節炎は米国で男性の17.9%、女性の24.2%に最も多くみられる(NHIS)。

さらに、受託製造により、製薬企業は製造能力を利用し、規制基準を遵守し、社内製造施設に関連するコストを最小限に抑えるサポートを受けることができます。製薬企業と受託製造業者との戦略的提携は、半固形製剤の効率的な製造に役立っており、医薬品の迅速な市場参入や既存製剤の最適化を促進しています。半固形製剤の社内製造ラインの設置・維持には多額の投資が必要です。これには、これらの剤形を混合、充填、包装するための特殊な設備や、効率的に運用するための専門知識が含まれます。受託製造業者(CMO)と提携することで、製薬会社はこれらの初期費用や継続的なメンテナンス費用を回避することができます。CMOは半固形製剤の製造に特化しており、スケールメリットがあるため、複数の顧客に対して専門知識や設備を活用することができます。

半固形製剤の受託製造市場は、製剤技術の進歩や患者中心のソリューションへの関心の高まりにより、革新的な開発が急増しています。製剤技術革新には、バイオアベイラビリティを高めるためのナノ化・微粉化粒子の使用や、安定性と性能を最適化するための高度な粒度分布技術が含まれます。製薬企業はまた、患者のコンプライアンスを優先し、使いやすいパッケージデザインや自己投与機能のイントロダクションを導入しています。製薬企業と受託製造業者との戦略的提携により、こうした特殊製剤の効率的な生産と迅速な市場参入が可能となっています。

市場は主に医薬品であるクリーム、軟膏、ゲルの需要拡大によって牽引されているが、CMOはこれらの半固形製剤に関する専門知識を活かして化粧品業界にも対応することができます。これにより、顧客基盤を拡大し、生産ラインを最適化することができます。さらに、外用スキンケア製品に対する消費者の関心の高まりは、CMOが化粧品会社と提携して革新的なクリーム、美容液、ローションを開発・製造するさらなる機会を生み出しています。医薬品部門と化粧品部門のこのような相乗効果が、市場全体の成長を後押ししています。

さらに、個別化医療の需要は、個人のニーズに合わせたカスタマイズされた半固形製剤形の開発に拍車をかけています。吸収促進成分や新規賦形剤も、これらの局所治療の有効性とバイオアベイラビリティを向上させるために活用されています。このような多面的な技術革新は、半固形製剤市場を変革し、皮膚、眼、慢性疼痛など幅広い症状に対して、より効果的で便利な、個人に合わせたソリューションを提供しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 半固形製剤受託製造市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し。
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 半固形製剤受託製造市場分析ツール
    • 業界分析 - ポーターのファイブフォース分析
    • PESTEL分析

第4章 半固形製剤受託製造市場:タイプ別の推定・動向分析

  • 市場シェア:タイプ別、2023年・2030年
  • セグメントダッシュボード
  • 世界の半固形製剤受託製造市場の展望:タイプ別
  • 市場規模と予測および動向分析、2018年~2030年
  • 局所
  • 経皮
  • 経口

第5章 半固形製剤受託製造市場:製品別の推定・動向分析

  • 市場シェア:製品別、2023年・2030年
  • セグメントダッシュボード
  • 世界の半固形製剤受託製造市場の展望:製品別
  • 市場規模と予測および動向分析、2018年~2030年
  • クリーム
  • 軟膏
  • ジェル
  • ローション
  • ペースト
  • その他

第6章 半固形製剤受託製造市場:最終用途別の推定・動向分析

  • 市場シェア:最終用途、2023年・2030年
  • セグメントダッシュボード
  • 世界の半固形製剤受託製造市場の展望:最終用途別
  • 市場規模と予測および動向分析、2018年~2030年
  • 製薬会社
  • 化粧品会社
  • その他

第7章 半固形製剤受託製造市場:企業規模別の推定・動向分析

  • 市場シェア:企業規模別、2023年・2030年
  • セグメントダッシュボード
  • 世界の半固形製剤受託製造市場の展望:企業規模別
  • 市場規模と予測および動向分析、2018年~2030年
  • 大規模企業
  • 中堅・中小企業
  • その他

第8章 半固形製剤受託製造市場:地域別の推定・動向分析

  • 市場シェア分析:地域別、2023年・2030年
  • 市場ダッシュボード:地域別
  • 市場規模と予測および動向分析、2018年~2030年:
  • 北米
    • 北米市場の推計・予測、2018年~2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州市場の推計・予測、2018年~2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • アジア太平洋市場の推計・予測、2018年~2030年
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ラテンアメリカ市場の推計・予測、2018年~2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカ市場の推計・予測:2018年~2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要な販売代理店とチャネルパートナー一覧
    • 主要顧客
    • 主要企業の市場シェア分析、2023年
  • 企業プロファイル
    • Lonza Group Ltd.
    • Lubrizol Life Science
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited
    • Bora Pharmaceutical CDMO
    • Ascendia Pharmaceuticals
    • Pierre Fabre group
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD
    • MedPharm Ltd
    • Catalent, Inc.
    • Recipharm AB
    • Aenova Group
    • Almac Group
    • Ajinomoto Bio-Pharma Services
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America semi-solid dosage contract manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 5 North America semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 7 U.S. semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 9 U.S. semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 11 Canada semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 12 Canada semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 13 Canada semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Canada semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 15 Mexico semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 16 Mexico semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 17 Mexico semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Mexico semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 19 Europe semi-solid dosage contract manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 21 Europe semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 22 Europe semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Europe semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 24 Germany semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 25 Germany semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 26 Germany semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 27 Germany semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 28 UK semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 29 UK semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 30 UK semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 31 UK semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 32 France semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 33 France semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 34 France semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 35 France semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 36 Italy semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 37 Italy semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 38 Italy semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Italy semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 40 Spain semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 41 Spain semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 42 Spain semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Spain semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 44 Denmark semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 45 Denmark semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 46 Denmark semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Denmark semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 48 Sweden semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 49 Sweden semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 50 Sweden semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 51 Sweden semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 52 Norway semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 53 Norway semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 54 Norway semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 55 Norway semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific semi-solid dosage contract manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 61 China semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 62 China semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 63 China semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 64 China semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 65 Japan semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 66 Japan semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 67 Japan semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Japan semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 69 India semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 70 India semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 71 India semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 72 India semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 73 South Korea semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 74 South Korea semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 75 South Korea semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 76 South Korea semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 77 Australia semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 78 Australia semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 79 Australia semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 80 Australia semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 81 Thailand semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 82 Thailand semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 83 Thailand semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 84 Thailand semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 85 Latin America semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 86 Latin America semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 87 Latin America semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Latin America semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 89 Brazil semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 90 Brazil semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 91 Brazil semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Brazil semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 93 Argentina semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 94 Argentina semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 95 Argentina semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 96 Argentina semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 97 MEA semi-solid dosage contract manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 99 MEA semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 100 MEA semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 101 MEA semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 102 South Africa semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 103 South Africa semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 104 South Africa semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 105 South Africa semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 110 UAE semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 111 UAE semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 112 UAE semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 113 UAE semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)
  • Table 114 Kuwait semi-solid dosage contract manufacturing market, by type, 2018 - 2030 (USD Million)
  • Table 115 Kuwait semi-solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 116 Kuwait semi-solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)
  • Table 117 Kuwait semi-solid dosage contract manufacturing market, by company size, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Semi-solid dosage contract manufacturing market: market outlook
  • Fig. 14 Semi-solid dosage contract manufacturing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Semi-solid dosage contract manufacturing market driver impact
  • Fig. 20 Semi-solid dosage contract manufacturing market restraint impact
  • Fig. 21 Semi-solid dosage contract manufacturing market strategic initiatives analysis
  • Fig. 22 Semi-solid dosage contract manufacturing market: Type movement analysis
  • Fig. 23 Semi-solid dosage contract manufacturing market: Type outlook and key takeaways
  • Fig. 24 Topical market estimates and forecast, 2018 - 2030
  • Fig. 25 Transdermal market estimates and forecast, 2018 - 2030
  • Fig. 26 Oral market estimates and forecast, 2018 - 2030
  • Fig. 27 Semi-solid dosage contract manufacturing Market: Product movement analysis
  • Fig. 28 Semi-solid dosage contract manufacturing market: Product outlook and key takeaways
  • Fig. 29 Creams market estimates and forecasts, 2018 - 2030
  • Fig. 30 Immunoassay market estimates and forecasts, 2018 - 2030
  • Fig. 31 Ointments market estimates and forecasts, 2018 - 2030
  • Fig. 32 Gels market estimates and forecasts, 2018 - 2030
  • Fig. 33 Lotions market estimates and forecasts, 2018 - 2030
  • Fig. 34 Pastes market estimates and forecasts, 2018 - 2030
  • Fig. 35 Others market estimates and forecast, 2018 - 2030
  • Fig. 36 Semi-solid dosage contract manufacturing market: End Use movement analysis
  • Fig. 37 Semi-solid dosage contract manufacturing market: End Use outlook and key takeaways
  • Fig. 38 Pharmaceutical companies market estimates and forecast, 2018 - 2030
  • Fig. 39 Cosmeceutical companies market estimates and forecast, 2018 - 2030
  • Fig. 40 Others market estimates and forecast, 2018 - 2030
  • Fig. 41 Semi-solid dosage contract manufacturing market: End use movement analysis
  • Fig. 42 Semi-solid dosage contract manufacturing market: End use outlook and key takeaways
  • Fig. 43 Large size companies market estimates and forecasts, 2018 - 2030
  • Fig. 44 Medium & small size companies market estimates and forecasts, 2018 - 2030
  • Fig. 45 Others market estimates and forecasts, 2018 - 2030
  • Fig. 46 Global semi-solid dosage contract manufacturing market: Regional movement analysis
  • Fig. 47 Global semi-solid dosage contract manufacturing market: Regional outlook and key takeaways
  • Fig. 48 Global semi-solid dosage contract manufacturing market share and leading players
  • Fig. 49 North America market share and leading players
  • Fig. 50 Europe market share and leading players
  • Fig. 51 Asia Pacific market share and leading players
  • Fig. 52 Latin America market share and leading players
  • Fig. 53 Middle East & Africa market share and leading players
  • Fig. 54 North America, by country
  • Fig. 55 North America
  • Fig. 56 North America market estimates and forecasts, 2018 - 2030
  • Fig. 57 U.S. key country dynamics
  • Fig. 58 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 59 Canada key country dynamics
  • Fig. 60 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 61 Mexico key country dynamics
  • Fig. 62 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 63 Europe
  • Fig. 64 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 65 UK key country dynamics
  • Fig. 66 UK market estimates and forecasts, 2018 - 2030
  • Fig. 67 Germany key country dynamics
  • Fig. 68 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 69 France key country dynamics
  • Fig. 70 France market estimates and forecasts, 2018 - 2030
  • Fig. 71 Italy key country dynamics
  • Fig. 72 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 73 Spain key country dynamics
  • Fig. 74 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 75 Denmark key country dynamics
  • Fig. 76 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 77 Sweden key country dynamics
  • Fig. 78 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 79 Norway key country dynamics
  • Fig. 80 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 81 Asia Pacific
  • Fig. 82 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 83 China key country dynamics
  • Fig. 84 China market estimates and forecasts, 2018 - 2030
  • Fig. 85 Japan key country dynamics
  • Fig. 86 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 87 India key country dynamics
  • Fig. 88 India market estimates and forecasts, 2018 - 2030
  • Fig. 89 Thailand key country dynamics
  • Fig. 90 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 91 South Korea key country dynamics
  • Fig. 92 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 93 Australia key country dynamics
  • Fig. 94 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 95 Latin America
  • Fig. 96 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 97 Brazil key country dynamics
  • Fig. 98 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 99 Argentina key country dynamics
  • Fig. 100 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 101 Middle East and Africa
  • Fig. 102 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 103 South Africa key country dynamics
  • Fig. 104 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 105 Saudi Arabia key country dynamics
  • Fig. 106 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 107 UAE key country dynamics
  • Fig. 108 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 109 Kuwait key country dynamics
  • Fig. 110 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 111 Market share of key market players- Semi-solid dosage contract manufacturing market
目次
Product Code: GVR-4-68040-345-3

Market Size & Trends

The global semi-solid dosage contract manufacturing market size was valued at USD 17.57 billion in 2023 and is projected to grow at a CAGR of 11.12% from 2024 to 2030. The rising demand for patient-friendly medications coupled with growing prevalence of chronic diseases such as skin diseases, arthritis, and pain management aids the market growth. Moreover, there is a growing demand for manufacturing outsourcing due to its cost-effectiveness. Furthermore, regulatory compliance and quality assurance, technological advancements including innovation in formulation technologies, are likely to boost their demand over the forecast period.

The high prevalence of chronic conditions such as skin diseases, arthritis and the requirement for pain management solutions due to the ageing population around the world is a major factor for the market growth. With an estimated 1.8 billion people affected by over 3,000 types of skin conditions at any given time, according to the World Health Organization, there's a massive demand for effective treatments. The U.S. population is experiencing a significant shift towards aging. According to the January 2024 fact sheet by the Population Reference Bureau, the number of Americans aged 65 and older is expected to surge from 58 million in 2022 to 82 million by 2050, representing a substantial 47% increase. Additionally, the proportion of the total population comprised of individuals aged 65 and older is projected to rise from 17% to 23%, marking the oldest age distribution in U.S. history.

In addition, according to the Global Burden of Disease Study 2021, skin diseases rank as the eighth leading cause of global health burden. Semi-solid dosage forms, such as creams and ointments, are a preferred method of administration for many skin diseases, offering a convenient and mess-free application. This surge in demand for skin condition and pain management treatments is propelling the growth of the market, as pharmaceutical companies seek out partners with the expertise to produce these medications efficiently and in large quantities. Further, according to the CDC report covering the period from 2019 to 2021, arthritis was most prevalent in 17.9% of men and 24.2% of women in the U.S. (NHIS).

Additionally, contract manufacturing enables pharmaceutical companies to access manufacturing capabilities, adhere to regulatory standards, and support to minimize costs associated with in-house production facilities. Strategic collaborations between pharmaceutical companies and contract manufacturers are instrumental in the efficient production of semi solid dosage forms, facilitating faster market entry for drugs further optimization of existing formulations. Setting up and maintaining in-house production lines for semi-solid medications requires substantial investments. This includes specialized equipment for mixing, filling, and packaging these dosage forms, as well as the expertise to operate them efficiently. By partnering with a contract manufacturer (CMO), pharmaceutical companies can bypass these upfront costs and ongoing maintenance expenses. CMOs specialize in semi-solid production and have economies of scale, allowing them to leverage their expertise and equipment for multiple clients.

The semi-solid dosage contract manufacturing market is witnessing a surge of innovative developments, driven by advancements in formulation technology and a growing focus on patient-centric solutions. Formulation innovations include the use of nano and micronized particles to enhance bioavailability, as well as sophisticated particle size distribution techniques to optimize stability and performance. Manufacturers are also prioritizing patient compliance, with the introduction of user-friendly packaging designs and self-administration features. Strategic collaborations between pharmaceutical companies and contract manufacturers are enabling efficient production and faster market entry of these specialized formulations.

While the market is primarily driven by the growing demand for pharmaceutical creams, ointments, and gels, CMOs can leverage their expertise in these semi-solid dosage forms to cater to the cosmetics industry as well. This allows them to expand their client base and optimize production lines. Furthermore, the growing consumer interest in topical skincare products creates additional opportunities for CMOs to partner with cosmetic companies in developing and manufacturing innovative creams, serums, and lotions. This synergy between the pharmaceutical and cosmetic sector helps to fuel the overall growth of the market.

Furthermore, the demand for personalized medicine is fueling the development of customized semi-solid dosage forms tailored to individual needs. Absorption-enhancing ingredients and novel excipients are also being leveraged to improve the efficacy and bioavailability of these topical treatments. These multifaceted innovations are transforming the semi-solid dosage form market, offering more effective, convenient, and personalized solutions for a wide range of skin, eye, and chronic pain conditions.

Global Semi-solid Dosage Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global semi-solid dosage contract manufacturing market report on the basis of type, product, end use, company size and region:

  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Topical
  • Transdermal
  • Oral
  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Creams
  • Ointments
  • Gels
  • Lotions
  • Pastes
  • Others
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceutical Companies
  • Cosmeceutical Companies
  • Others
  • Company Size Outlook (Revenue, USD Million, 2018 - 2030)
  • Large Size Companies
  • Medium & Small Size Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

China

Japan

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. End Use
    • 1.2.4. Company Size
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Semi-solid Dosage Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising demand for patient-friendly medications
      • 3.2.1.2. Growing prevalence of chronic diseases
      • 3.2.1.3. Growing demand of manufacturing outsourcing
      • 3.2.1.4. Regulatory Compliance
      • 3.2.1.5. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Quality control challenges
  • 3.3. Semi-solid Dosage Contract Manufacturing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Semi-solid Dosage Contract Manufacturing Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Semi-solid Dosage Contract Manufacturing Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Topical
    • 4.5.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Transdermal
    • 4.6.1. Transdermal market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Oral
    • 4.7.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Semi-solid Dosage Contract Manufacturing Market: Product Estimates & Trend Analysis

  • 5.1. Product Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Semi-solid Dosage Contract Manufacturing Market by Product Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Creams
    • 5.5.1. Creams market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Ointments
    • 5.6.1. Ointments market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Gels
    • 5.7.1. Gels market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Lotions
    • 5.8.1. Lotions market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Pastes
    • 5.9.1. Pastes market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. Other
    • 5.10.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Semi-solid Dosage Contract Manufacturing Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Semi-solid Dosage Contract Manufacturing Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Pharmaceutical companies
    • 6.5.1. Pharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Cosmeceutical companies
    • 6.6.1. Cosmeceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Other
    • 6.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Semi-solid Dosage Contract Manufacturing Market: Company Size Estimates & Trend Analysis

  • 7.1. Company Size Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Semi-solid Dosage Contract Manufacturing Market by Company Size Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Large Size Companies
    • 7.5.1. Large size companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Medium & Small Size Companies
    • 7.6.1. Medium & small size companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Semi-solid Dosage Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory Scenario
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory Scenario
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory Scenario
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory Scenario
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Regulatory framework
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Regulatory framework
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.9. Denmark
      • 8.5.9.1. Key country dynamics
      • 8.5.9.2. Regulatory Scenario
      • 8.5.9.3. Competitive scenario
      • 8.5.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory Scenario
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory Scenario
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory Scenario
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory Scenario
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory Scenario
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory Scenario
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory Scenario
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory Scenario
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory Scenario
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Regulatory Scenario
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key country dynamics
      • 8.8.5.2. Regulatory framework
      • 8.8.5.3. Competitive scenario
      • 8.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
  • 9.4. Company Profiles
    • 9.4.1. Lonza Group Ltd.
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Others benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Lubrizol Life Science
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Others benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Cambrex Corporation
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Others benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Contract Pharmaceuticals Limited
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Others benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Bora Pharmaceutical CDMO
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Others benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Ascendia Pharmaceuticals
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Others benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Pierre Fabre group
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Others benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Piramal Pharma Solutions
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Others benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. DPT Laboratories, LTD
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Others benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. MedPharm Ltd
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Others benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. Catalent, Inc.
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Others benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. Recipharm AB
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Others benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. Aenova Group
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Others benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. Almac Group
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Others benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. Ajinomoto Bio-Pharma Services
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Others benchmarking
      • 9.4.15.4. Strategic initiatives